IL17A and neoplasm: Th17 contributes to poorer prognosis of LUSC by expressing the transcription factors RORγt/RORC2 (mouse/human) and RORα, which drive Th17 differentiation and produce pro-inflammatory cytokines IL-17, which has been shown to promote tumor growth by increasing angiogenesis, metastasis and macrophage infiltration into tumors.